A Novel Polyacrylamide Magnetic Nanoparticle Contrast Agent for Molecular Imaging using MRI

A novel Polyacrylamide superparamagnetic iron oxide nanoparticle platform is described which has been synthetically prepared such that multiple crystals of iron oxide are encapsulated within a single Polyacrylamide matrix ( P oly A crylamide M agnetic [PAM] nanoparticles). This formulation provides...

Full description

Saved in:
Bibliographic Details
Main Authors: Bradford A. Moffat, G. Ramachandra Reddy, Patrick McConville, Daniel E. Hall, Thomas L. Chenevert, Raoul R. Kopelman, Martin Philbert, Ralph Weissleder, Alnawaz Rehemtulla, Brian D. Ross
Format: Article
Language:English
Published: SAGE Publishing 2003-10-01
Series:Molecular Imaging
Online Access:https://doi.org/10.1162/15353500200303163
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841564514821079040
author Bradford A. Moffat
G. Ramachandra Reddy
Patrick McConville
Daniel E. Hall
Thomas L. Chenevert
Raoul R. Kopelman
Martin Philbert
Ralph Weissleder
Alnawaz Rehemtulla
Brian D. Ross
author_facet Bradford A. Moffat
G. Ramachandra Reddy
Patrick McConville
Daniel E. Hall
Thomas L. Chenevert
Raoul R. Kopelman
Martin Philbert
Ralph Weissleder
Alnawaz Rehemtulla
Brian D. Ross
author_sort Bradford A. Moffat
collection DOAJ
description A novel Polyacrylamide superparamagnetic iron oxide nanoparticle platform is described which has been synthetically prepared such that multiple crystals of iron oxide are encapsulated within a single Polyacrylamide matrix ( P oly A crylamide M agnetic [PAM] nanoparticles). This formulation provides for an extremely large T 2 and T 2 * relaxivity of between 620 and 1140 sec −1 mM −1 . Administration of PAM nanoparticles into rats bearing orthotopic 9L gliomas allowed quantitative pharmacokinetic analysis of the uptake of nanoparticles in the vasculature, brain, and glioma. Addition of polyethylene glycol of varying sizes (0.6, 2, and 10 kDa) to the surface of the PAM nanoparticles resulted in an increase in plasma half-life and affected tumor uptake and retention of the nanoparticles as quantified by changes in tissue contrast using MRI. The flexible formulation of these nanoparticles suggests that future modifications could be accomplished allowing for their use as a targeted molecular imaging contrast agent and/or therapeutic platform for multiple indications.
format Article
id doaj-art-091c5f57b40142e9b8e7ae86b859dd8f
institution Kabale University
issn 1536-0121
language English
publishDate 2003-10-01
publisher SAGE Publishing
record_format Article
series Molecular Imaging
spelling doaj-art-091c5f57b40142e9b8e7ae86b859dd8f2025-01-02T22:37:33ZengSAGE PublishingMolecular Imaging1536-01212003-10-01210.1162/1535350020030316310.1162_15353500200303163A Novel Polyacrylamide Magnetic Nanoparticle Contrast Agent for Molecular Imaging using MRIBradford A. Moffat0G. Ramachandra Reddy1Patrick McConville2Daniel E. Hall3Thomas L. Chenevert4Raoul R. Kopelman5Martin Philbert6Ralph Weissleder7Alnawaz Rehemtulla8Brian D. Ross9University of MichiganMolecular Therapeutics Inc.Molecular Therapeutics Inc.University of MichiganUniversity of MichiganUniversity of MichiganUniversity of MichiganMassachusetts General HospitalUniversity of MichiganUniversity of MichiganA novel Polyacrylamide superparamagnetic iron oxide nanoparticle platform is described which has been synthetically prepared such that multiple crystals of iron oxide are encapsulated within a single Polyacrylamide matrix ( P oly A crylamide M agnetic [PAM] nanoparticles). This formulation provides for an extremely large T 2 and T 2 * relaxivity of between 620 and 1140 sec −1 mM −1 . Administration of PAM nanoparticles into rats bearing orthotopic 9L gliomas allowed quantitative pharmacokinetic analysis of the uptake of nanoparticles in the vasculature, brain, and glioma. Addition of polyethylene glycol of varying sizes (0.6, 2, and 10 kDa) to the surface of the PAM nanoparticles resulted in an increase in plasma half-life and affected tumor uptake and retention of the nanoparticles as quantified by changes in tissue contrast using MRI. The flexible formulation of these nanoparticles suggests that future modifications could be accomplished allowing for their use as a targeted molecular imaging contrast agent and/or therapeutic platform for multiple indications.https://doi.org/10.1162/15353500200303163
spellingShingle Bradford A. Moffat
G. Ramachandra Reddy
Patrick McConville
Daniel E. Hall
Thomas L. Chenevert
Raoul R. Kopelman
Martin Philbert
Ralph Weissleder
Alnawaz Rehemtulla
Brian D. Ross
A Novel Polyacrylamide Magnetic Nanoparticle Contrast Agent for Molecular Imaging using MRI
Molecular Imaging
title A Novel Polyacrylamide Magnetic Nanoparticle Contrast Agent for Molecular Imaging using MRI
title_full A Novel Polyacrylamide Magnetic Nanoparticle Contrast Agent for Molecular Imaging using MRI
title_fullStr A Novel Polyacrylamide Magnetic Nanoparticle Contrast Agent for Molecular Imaging using MRI
title_full_unstemmed A Novel Polyacrylamide Magnetic Nanoparticle Contrast Agent for Molecular Imaging using MRI
title_short A Novel Polyacrylamide Magnetic Nanoparticle Contrast Agent for Molecular Imaging using MRI
title_sort novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using mri
url https://doi.org/10.1162/15353500200303163
work_keys_str_mv AT bradfordamoffat anovelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT gramachandrareddy anovelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT patrickmcconville anovelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT danielehall anovelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT thomaslchenevert anovelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT raoulrkopelman anovelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT martinphilbert anovelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT ralphweissleder anovelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT alnawazrehemtulla anovelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT briandross anovelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT bradfordamoffat novelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT gramachandrareddy novelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT patrickmcconville novelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT danielehall novelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT thomaslchenevert novelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT raoulrkopelman novelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT martinphilbert novelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT ralphweissleder novelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT alnawazrehemtulla novelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri
AT briandross novelpolyacrylamidemagneticnanoparticlecontrastagentformolecularimagingusingmri